P908 Real-life effectiveness and safety of tofacitinib and vedolizumab as a second-line therapy in anti-TNFs experienced patients ulcerative colitis: preliminary results of an IGIBD study (VE2TO-UC)
Authors: Noviello D , Savarino E , Fries W , Fantini M C , Conforti F , Orlando A , Ribaldone D G , Mocci G , Viganò C , Festa S , Spagnuolo R , Campigotto M , Grossi L , Gravina A G , Principi M , Imperatore N , Carvalhas A , Scardino G , Scaldaferri F , Ceccarelli L , Biancone L , Di Sario A , De Barba C , De Francesco C , Calderone S , Onali S , Vecchi M , Ventimiglia M , Caprioli F 
Published: January 2024

Background

Drug positioning in ulcerative colitis (UC) patients refractory to anti-tumor necrosis factor (TNF) is still debated. We aimed to compare the real-life effectiveness and safety of tofacitinib and vedolizumab as second-line therapy in anti-TNFs experienced UC patients.

Methods

In this Italian multicenter cohort study, we retrospectively included consecutive UC adult patients exposed to ≥ 1 anti-TNF agent starting tofacitinib or vedolizumab. Clinical remission (defined as partial Mayo score (PMS) &lt;3 and no subscore &gt;1) and corticosteroid-free clinical remission (CFREM) were assessed at week 26. Patients who discontinued treatment due to a primary or secondary non-response, adverse events, or intolerance were considered as treatment failure and classified as non-responders. The primary outcome was to compare clinical remission in tofacitinib- and vedolizumab-treated patients at week 26. Propensity score with inverse probability of treatment weighting (IPTW) was used to adjust for confounding, including sex, age at drug initiation, age at diagnosis, smoking habit, disease extension, use of immunosuppressant and steroids at baseline, disease activity at baseline by PMS, reason for anti-TNF discontinuation. Multiple imputation was used for missing data. Venous thromboembolism event, herpes zoster reactivation, major cardiovascular adverse event, severe lymphopenia, initiation or escalation of cholesterol-lowering drugs, hospitalization, surgery, dysplasia or colorectal carcinoma, and death were assessed for the safety profile.

Results

Overall, 99 tofacitinib- and 230 vedolizumab-treated patients were included. Baseline characteristics are summarized in Table 1. The groups were comparable except that tofacitinib-treated patients were younger and of pediatric onset, with lower comorbidities and cardiovascular risk factors. Of note, 22 patients were excluded due to a lack of sufficient follow-up. After IPTW analysis, no difference between tofacitinib- and vedolizumab-treated patients in terms of clinical remission 1.23 (0.68 – 2.23) and CFREM 1.27 (0.71 – 2.29) was observed at week 26. Similar results in terms of clinical remission 1.13 (0.60 – 2.14) and CFCR 1.16 (0.62 – 2.20) were obtained when analyzing patients with a baseline PMS ≥ 2 (Figure 1). No difference was observed in terms of adverse events in the two groups.

Conclusion

Our preliminary results suggest no difference in terms of clinical remission and CFREM of tofacitinib and vedolizumab as second-line therapy in anti-TNFs experienced UC patients at the 26th week. Safety was consistent with known tofacitinib and vedolizumab profiles.